ArticleGastro hep advances2025
The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04197479 (A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Who cites it
3 citing papers in PubMed.
- Evidence Supporting Utility of the Oral Cholate Challenge Test of Liver Function and Physiology to Aid Clinical Management: A Review of Analytical and Clinical Validation Studies.Gastro hep advances · 2026Review
- When should I repeat the endoscopy in my patient with compensated cirrhosis, whom I just scoped and who had no or small varices?Translational gastroenterology and hepatology · 2026Article
- Beyond Liver Function Tests, Liver Stiffness, and Portal Pressure: Portal-Systemic Shunting as a New Endpoint for Clinical Trials of Cirrhosis and Portal Hypertension.Gastro hep advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: In this study of metabolic dysfunction-associated steatohepatitis (MASH)-related Child-Pugh A cirrhosis (MASH cirrhosis), we used the cholate challenge test to quantify baseline disease severity and the subsequent impact of resmetirom treatment. Methods: Thirty-two subjects enrolled in the Phase 3 open-label MAESTRO-NAFLD-1 trial with MASH cirrhosis underwent baseline dual cholate shunt testing, and 25 had subsequent retesting at 28 and 48 weeks. Blood was sampled from 0 to 90 minutes, serum concentrations measured, and parameters of function (disease severity index [DSI]), portal-systemic shunting (SHUNT%), and clinical risk (RISK ACE) were calculated. Responders were defined by > 2-point decrease in DSI, stable subjects by a ΔDSI within ±2, and nonresponders by > 2-point increase. Results: Baseline DSI (22 ± 7) and SHUNT% (36% ± 16%) were consistent with significant functional impairment and portal-systemic shunting. Responder rates were 14% by 28 weeks and 38% by 48 weeks ( Conclusion: MASH cirrhosis is characterized by a broad spectrum of hepatic impairment and portal-systemic shunting. DSI, SHUNT%, and RISK ACE may provide early estimates of potential clinical benefit with resmetirom treatment. MAESTRO-NAFLD-1 was registered at ClinicalTrials.gov (NCT04197479).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.